Dr. Rowan Martindale, a paleoecologist and geobiologist at the University of Texas at Austin, was walking through the Dadès Valley in the Central High Atlas Mountains of Morocco when she saw something ...
The Daily Overview on MSN
Nvidia teams with biotech giants to supercharge AI drug discovery
Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...
Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...
Grab-and-go missions to asteroids have provided some of the most scientifically valuable samples since the Apollo ...
Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly. On December 17, 2025, JPMorgan ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...
The original version of this story appeared in Quanta Magazine. Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback